Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | JAK1 | P23458 | 7/20 | 0.40 |
| ▸ | PGR | P06401 | 5/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610721 | 0.89 | CRHR1 (0.39) | JAK2JAK1PGRNR3C1NR3C2 | |
| SCHEMBL16726645 | 0.87 | BRD4 (0.33) | JAK2JAK1 | |
| SCHEMBL16623452 | 0.85 | BRD9 (0.31) | — | |
| SCHEMBL16623520 | 0.83 | MAPT (0.36) | ARKDRTGFBR1 | |
| SCHEMBL16610998 | 0.65 | CRHR1 (0.40) | JAK2PGRNR3C1NR3C2AR | |
| SCHEMBL16794633 | 0.62 | MAPT (0.62) | — | |
| SCHEMBL1631024 | 0.62 | PGR (0.83) | PGRNR3C1NR3C2AR | |
| SCHEMBL16623471 | 0.61 | CCNE2 (0.39) | KDRTEK | |
| SCHEMBL15536272 | 0.61 | MCL1 (0.52) | ARCYP11B2 | |
| SCHEMBL16602028 | 0.59 | PGR (0.40) | PGRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK2 1/4885JAK1 2/4885PGR 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.